SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese operator of aesthetic medical clinics and provider of consulting services, has completed a strategic investment in OrangeTwist, a U.S.-based medspa chain specializing in non-invasive aesthetic treatments. The partnership, announced late last month, marks SBC's official foray into the U.S. market, which the company estimates will grow from $34 billion today to $48 billion by 2030, driven by demand for non-surgical treatments such as injectables, fillers, laser treatments and body contouring.
OrangeTwist currently operates 24 locations across six U.S. states, offering injectable, energy-based and regenerative treatments. Following the partnership, the two companies will pursue joint operations to leverage synergies in the U.S. and Asia. SBC Medical brings funding and professional expertise to help OrangeTwist enhance its offerings and open new locations more quickly, addressing what the industry calls 'white space'—cities with high demand but few competitors. Healthcare-focused private equity firm Hildred Capital and Athyrium Capital are also longstanding institutional shareholders in OrangeTwist.
Stephen Rodgers, global head of planning and strategy at SBC Medical, told Benzinga in an interview that the company plans more strategic investments in the U.S. 'As part of SBC’s global expansion, we are working hard to find local partnerships rather than copying and pasting what we did in Japan,' Rodgers said. He noted that SBC looks for partners that align with its mission, hold a leadership position and can scale, similar to OrangeTwist. The companies also plan to jointly develop branded products and sell existing products in each other's spas.
Beyond aesthetics, SBC is positioning itself in the longevity industry, which is shifting from increasing lifespan to boosting 'healthspan' through personalized, preventative and tech-driven solutions. According to Gabelli Research, the global anti-aging market, valued at approximately $85 billion in 2025, is expected to surpass $120 billion by 2030, growing at a CAGR of 7%. North America accounts for about 30% of the market, while Asia also shows robust growth. Key trends include AI-powered diagnostics, GLP-1 weight-loss drugs and regenerative therapies like stem cells, areas where SBC believes it is well-positioned with its existing infrastructure.
SBC Medical is also expanding in Japan and Southeast Asia, using its proven business model to help Asian clinics with one-stop management, including staff training, better pricing for medical equipment and management services. The company's global strategy rests on three tenets: partnering with high-performing regional operators, deploying expertise to drive efficiencies, and securing first-mover advantages. Non-invasive cosmetic treatments are ideally suited for Asian markets, where customers prefer natural-looking treatments with minimal recovery times. By standardizing services, SBC ensures consistent quality and pricing across Japan, Thailand and Singapore.
To learn more about SBC Medical, click here. This content was originally published on Benzinga. Read further disclosures here.
